Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-l...
Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapy
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Background
The majority of urothelial cancers (UC) harbor alterations in retinoblastoma (Rb) pathway genes that can lead to loss of Rb tumour suppressor function. Palbociclib is an oral, selective inhibitor of CDK 4/6 that restores Rb function and promotes cell cycle arrest.
Methods
In this phase II trial, patients with metastatic platinum...
Alternative Titles
Full title
Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapy
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6189143
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6189143
Other Identifiers
ISSN
0007-0920
E-ISSN
1532-1827
DOI
10.1038/s41416-018-0229-0
